Association of Level and Increase in D-Dimer With All-Cause Death and Poor Functional Outcome After Ischemic Stroke

Huiqing Hou1,2,3,4, Xianglong Xiang1,2,3, Yuesong Pan1,2,3

  • 1Department of Neurology Beijing Tiantan Hospital, Capital Medical University Beijing China.

Insights

High D-dimer levels and increases between baseline and 90 days are linked to worse outcomes in stroke patients. This study highlights D-dimer as a key biomarker for predicting mortality and functional decline after ischemic stroke.

Area of Science:

  • Neurology
  • Hematology
  • Biomarkers

Background:

  • D-dimer is a recognized coagulation biomarker associated with adverse outcomes in stroke.
  • Understanding its role in predicting long-term prognosis is crucial for patient management.

Purpose of the Study:

  • To investigate the association between D-dimer levels and their changes over time with all-cause mortality and poor functional outcomes.
  • To analyze D-dimer levels at baseline and 90 days post-event in patients with ischemic stroke or transient ischemic attack.

Main Methods:

  • Data from 10,518 patients within 7 days and 6,268 at 90 days from the Third China National Stroke Registry (CNSRIII) study were analyzed.
  • Multivariable Cox and logistic regression models assessed the association of D-dimer levels with 1-year all-cause death and poor functional outcomes (modified Rankin Scale ≥3).

Main Results:

  • Higher baseline D-dimer levels were significantly associated with increased risk of all-cause death (aHR, 1.77) and poor functional outcome (aOR, 1.49) at 1 year.
  • Elevated D-dimer levels at 90 days also independently predicted poor outcomes.
  • An increase in D-dimer from baseline to 90 days was linked to higher mortality (aHR, 1.99) but not functional outcome.

Conclusions:

  • Elevated D-dimer levels at baseline and 90 days are significant predictors of poor outcomes in ischemic stroke and transient ischemic attack patients.
  • The increase in D-dimer levels between baseline and 90 days is associated with increased mortality risk.
  • D-dimer serves as a valuable prognostic biomarker in the management of stroke patients.

Related Concept Videos

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
126
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.7K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
119
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
95
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
563